EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

Novel Targeted Therapies for Eosinophil-Associated Diseases and Allergy

(2015) Susanne Radonjic-Hoesli et al.   Annual Review of Pharmacology and Toxicology

Neues von der internationalen Leitlinie für Diagnostik und Therapie der chronischen Urtikaria

(2015) Marcus Maurer et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Length Of Avoidance Period Following Peanut Oral Immunotherapy Influences Effector Cell Suppression and Clinical Outcomes

(2014) Michael D. Kulis et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and safety of an anti–IL-13 mAb in patients with severe asthma: A randomized trial

(2014) Erika H. De Boever et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Adverse reactions to biologic agents and their medical management

(2014) Onur Boyman et al.   Nature Reviews Rheumatology

Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses

(2014) Gail M. Gauvreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

(2014) Lisa A. Beck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production

(2014) G. M. Gauvreau et al.   Science Translational Medicine

The consequences of not having eosinophils

(2013) G. J. Gleich et al.   ALLERGY

Schnitzler's syndrome: diagnosis, treatment, and follow-up

(2013) A. Simon et al.   ALLERGY

Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma

(2013) William W. Busse et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Severe Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab

(2013) Anna Agusti-Mejias et al.   Annals of Dermatology

Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss Syndrome

(2013) Frank Moosig et al.   ANNALS OF INTERNAL MEDICINE

Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy

(2013) Nicola A. Hanania et al.   ANNALS OF INTERNAL MEDICINE

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

OX40L blockade and allergen-induced airway responses in subjects with mild asthma

(2013) G. M. Gauvreau et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Omalizumab: A Review of its Use in Patients with Severe Persistent Allergic Asthma

(2013) Kate McKeage   DRUGS

Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis

(2013) R. B. Moss   EUROPEAN RESPIRATORY JOURNAL

New era of biologic therapeutics in atopic dermatitis

(2013) Emma Guttman-Yassky et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids

(2013) Michael Noonan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report

(2013) A. Wesley Burks et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study

(2013) Karoline Krause et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Anti–IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis

(2013) Iris M. Otani et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

(2013) Michel Laviolette et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

(2013) Allen Kaplan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis

(2013) Martin Metz et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

(2013) Dominique Baeten et al.   LANCET

Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

(2013) Marcus Maurer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab in Persistent Asthma with Elevated Eosinophil Levels

(2013) Sally Wenzel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Omalizumab in the management of steroid dependent Allergic Bronchopulmonary Aspergillosis (ABPA) complicating Cystic Fibrosis

(2013) Rachel Wong et al.   Paediatric Respiratory Reviews

Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy

(2013) Matthias Volkmar Kopp et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: A synthesis of published evidence

(2013) Kalliopi Tanou et al.   PEDIATRIC PULMONOLOGY

Successful management of Churg-Strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: First documented pediatric case

(2013) E. Iglesias et al.   PEDIATRIC PULMONOLOGY

Efficacy of Anti-Interleukin-5 Therapy with Mepolizumab in Patients with Asthma: A Meta-Analysis of Randomized Placebo-Controlled Trials

(2013) Yao Liu et al.   PLoS One

A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma

(2013) Chad K Oh et al.   RESPIRATORY RESEARCH

Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study

(2012) K. Krause et al.   ALLERGY

Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria

(2012) Christine Hahjin Song et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome

(2012) Heleen D de Koning et al.   ANNALS OF THE RHEUMATIC DISEASES

Biologic drugs in autoinflammatory syndromes

(2012) Roberta Caorsi et al.   AUTOIMMUNITY REVIEWS

A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics

(2012) Peter Hodsman et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study

(2012) Bart van Hartingsveldt et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study

(2012) P. Rich et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-Term Follow-Up of Patients With Hypereosinophilic Syndrome Treated With Alemtuzumab, an Anti-CD52 Antibody

(2012) Paolo Strati et al.   Clinical Lymphoma Myeloma & Leukemia

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

(2012) Edward Piper et al.   EUROPEAN RESPIRATORY JOURNAL

Tralokinumab for uncontrolled asthma

(2012) Ileana Antohe et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti–IL-4 receptor α antagonist

(2012) Rebecca E. Slager et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Novel targeted therapies for eosinophilic disorders

(2012) Michael E. Wechsler et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes

(2012) Florence E. Roufosse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma

(2012) Philippe Gevaert et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Marketing approval of mogamulizumab

(2012) Alain Beck et al.   mAbs

Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab

(2012) D Bedoret et al.   Mucosal Immunology

Therapies for allergic inflammation: refining strategies to induce tolerance

(2012) Cezmi A Akdis   NATURE MEDICINE

Innate and adaptive immune responses in asthma

(2012) Stephen T Holgate   NATURE MEDICINE

The potential of biologics for the treatment of asthma

(2012) Girolamo Pelaia et al.   NATURE REVIEWS DRUG DISCOVERY

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma

(2012) Makoto Hoshino et al.   RESPIRATION

Oral Immunotherapy for Food Allergy: Towards a New Horizon

(2012) Evelyne Khoriaty et al.   Allergy Asthma & Immunology Research

Can anti-IgE therapy prevent airway remodeling in allergic asthma?

(2011) K. F. Rabe et al.   ALLERGY

Allergic bronchopulmonary aspergillosis and omalizumab

(2011) I. Tillie-Leblond et al.   ALLERGY

Reslizumab for Poorly Controlled, Eosinophilic Asthma

(2011) Mario Castro et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis

(2011) G. Gualdi et al.   BRITISH JOURNAL OF DERMATOLOGY

Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor

(2011) N. A. Molfino et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Omalizumab: Anti-IgE Therapy in Allergy

(2011) Matthias Volkmar Kopp   CURRENT ALLERGY AND ASTHMA REPORTS

Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma

(2011) Aasia Ghazi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efalizumab

(2011) Marina Talamonti et al.   Expert Opinion On Drug Safety

An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children With Eosinophilic Esophagitis

(2011) Amal H. Assa'ad et al.   GASTROENTEROLOGY

Treatment of severe refractory adult atopic dermatitis with ustekinumab

(2011) Rafael Puya et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy

(2011) Hugh A. Sampson et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies

(2011) Soumya D. Chakravarty et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Future therapies for food allergies

(2011) Anna Nowak-Węgrzyn et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome

(2011) Jan Lötvall et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy

(2011) Kari C. Nadeau et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis

(2011) Philippe Gevaert et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial

(2011) Jonathan M. Spergel et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Treatment of refractory chronic urticaria with tumor necrosis factor–alfa inhibitors

(2011) Lindsay H. Wilson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

(2011) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Lebrikizumab Treatment in Adults with Asthma

(2011) Jonathan Corren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children

(2011) William W. Busse et al.   NEW ENGLAND JOURNAL OF MEDICINE

Population PK and IgE Pharmacodynamic Analysis of a Fully Human Monoclonal Antibody Against IL4 Receptor

(2011) Tarundeep Kakkar et al.   PHARMACEUTICAL RESEARCH

Airway remodeling in asthma: New mechanisms and potential for pharmacological intervention

(2011) Pierre-Olivier Girodet et al.   PHARMACOLOGY & THERAPEUTICS

Effects of omalizumab in Aspergillus-associated airway disease

(2011) L. A. Perez-de-Llano et al.   THORAX

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

(2011) Joseph M Parker et al.   BMC Pulmonary Medicine

Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy

(2010) M. Metz et al.   ALLERGY

Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria

(2010) A. Groffik et al.   ALLERGY

A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma

(2010) Jonathan Corren et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma

(2010) Gail M. Gauvreau et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial

(2010) S. T. Holgate et al.   EUROPEAN RESPIRATORY JOURNAL

B-cell targeted therapies in human autoimmune diseases: an updated perspective

(2010) Michael J. Townsend et al.   IMMUNOLOGICAL REVIEWS

Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria

(2010) Martin Metz et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma

(2010) William W. Busse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Sustained response to mepolizumab in refractory Churg-Strauss syndrome

(2010) Jean-Emmanuel Kahn et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

A review of treatment with mepolizumab, an anti–IL-5 mAb, in hypereosinophilic syndromes and asthma

(2010) William W. Busse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome

(2010) Florence Roufosse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome

(2010) Sophia Kim et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma

(2010) Marc Massanari et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Future forms of immunotherapy

(2010) Thomas B. Casale et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Italian real-life experience of omalizumab

(2010) M. Cazzola et al.   RESPIRATORY MEDICINE

Effects of omalizumab on markers of inflammation in patients with allergic asthma

(2009) S. Holgate et al.   ALLERGY

Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis

(2009) K. Kontou-Fili et al.   ALLERGY

Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis

(2009) F. Brinkmann et al.   ALLERGY

A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma

(2009) Sally E. Wenzel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers

(2009) Barbara White et al.   CLINICAL THERAPEUTICS

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial

(2009) A Straumann et al.   GUT

Re-Treatment with Omalizumab at One Year Interval for Japanese Cedar Pollen-Induced Seasonal Allergic Rhinitis Is Effective and Well Tolerated

(2009) Satoshi Ogino et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Therapy of autoinflammatory syndromes

(2009) Hal M. Hoffman   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria

(2009) Peter D. Arkwright   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

(2009) K Ibler et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Asthma

(2009) Christopher H. Fanta   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

(2009) Pranabashis Haldar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

(2009) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously

(2009) Wolfgang Kamin et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis

(2009) Daniel E. Furst   SEMINARS IN ARTHRITIS AND RHEUMATISM

ALLERGY Net: High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis

(2008) K. Kontou-Fili   ALLERGY

Successful treatment of solar urticaria with anti-immunoglobulin E therapy

(2008) O. Güzelbey et al.   ALLERGY

Daclizumab Improves Asthma Control in Patients with Moderate to Severe Persistent Asthma

(2008) William W. Busse et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

(2008) C Salliot et al.   ANNALS OF THE RHEUMATIC DISEASES

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

(2008) M. V. Kopp et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia

(2008) S. Verstovsek et al.   CLINICAL CANCER RESEARCH

One Year Administration of Anti-IgE to a Patient with Churg-Strauss Syndrome

(2008) Pedro Giavina-Bianchi et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema

(2008) Dagmar Simon et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Anti-CD20 (rituximab) treatment for atopic eczema

(2008) Anna Šedivá et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Omalizumab and Churg-Strauss syndrome

(2008) Pedro Giavina-Bianchi et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Anti-CD20 (rituximab) treatment improves atopic eczema

(2008) Dagmar Simon et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Treatment of chronic autoimmune urticaria with omalizumab

(2008) Allen P. Kaplan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Churg-Strauss Vasculitis in a Patient Treated with Omalizumab

(2008) Elana Bargagli et al.   JOURNAL OF ASTHMA

Alefacept for moderate to severe atopic dermatitis: A pilot study in adults

(2008) Danielle K. Moul et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

(2008) Marc E. Rothenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis

(2008) Jacquelyn M. Zirbes et al.   PEDIATRIC PULMONOLOGY

The role of a soluble TNF  receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial

(2008) J B Morjaria et al.   THORAX

Apparent response to anti-IgE therapy in two patients with refractory "forme fruste" of Churg-Strauss syndrome

(2008) S Pabst et al.   THORAX